Floatz logo

FENTANYL

Cervical Cancer

National Cancer Institute (NCI)Small moleculePhase 3Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
65/ 100

Competitive context

159 Active assets in the Cervical Cancer cohort.

Asset / SponsorPhaseRating
Vinorelbine
UNICANCER
Phase 2BBB
Indocyanine Green
Istanbul University
Phase 4BB
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 3B
TECHNETIUM-99
Institut de Cancérologie de Lorraine
Phase 3B

View all 50 →

Same molecule, other indications

FENTANYL is also rated in:

Low Back PainDormant
BBB
Indicative ·
75 / 100
View asset →
PainDormant
BBB
Indicative ·
74 / 100
View asset →
chronic pain syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →